ANEB RSI Chart
Last 7 days
-23.6%
Last 30 days
-23.3%
Last 90 days
-19.3%
Trailing 12 Months
11.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 222.8K | 0 | 0 | 0 |
2023 | 71.1K | 92.4K | 0 | 163.5K |
2022 | 0 | 7.3K | 28.6K | 49.9K |
2021 | 0 | 1.0K | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 18, 2023 | english aron r. | gifted | - | - | -300,000 | - |
Dec 18, 2023 | english aron r. | gifted | - | - | 300,000 | - |
Nov 13, 2023 | english aron r. | acquired | - | - | 300,000 | - |
Dec 17, 2021 | english aron r. | bought | 2,634 | 6.5858 | 400 | - |
Dec 14, 2021 | english aron r. | bought | 2,428 | 5.895 | 412 | - |
Dec 03, 2021 | english aron r. | bought | 26,685 | 5.93 | 4,500 | - |
Dec 02, 2021 | english aron r. | bought | 73,330 | 5.3 | 13,836 | - |
May 06, 2021 | english aron r. | acquired | 4,999,750 | 7.00 | 714,250 | - |
May 06, 2021 | english aron r. | acquired | 5,000,000 | 7.00 | 714,286 | - |
Which funds bought or sold ANEB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Ikarian Capital, LLC | unchanged | - | 71,038 | 453,064 | 0.05% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 179,649 | 1,145,760 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -10.00 | - | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | sold off | -100 | -2,945 | - | -% |
May 15, 2024 | 22NW, LP | unchanged | - | 2,414,830 | 15,401,300 | 13.27% |
May 15, 2024 | BOOTHBAY FUND MANAGEMENT, LLC | unchanged | - | 8,540 | 54,467 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -43.55 | -7,281 | 14,746 | -% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -50.00 | -1,006,810 | 1,466,780 | 0.08% |
May 15, 2024 | Royal Bank of Canada | reduced | -46.48 | - | - | -% |
May 13, 2024 | UBS Group AG | new | - | 413 | 413 | -% |
Peers (Alternatives to Anebulo Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Anebulo Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q2 |
Revenue | -9.8% | 68,084 | 75,522 | 6.00 | 79,152 | 8,816 | - | - | - |
Operating Expenses | -39.7% | 1,664,251 | 2,760,459 | 2,494,389 | 2,864,041 | 3,813,122 | 2,612,047 | 2,325,484 | 2,484,705 |
S&GA Expenses | -100.0% | - | 1,697,787 | 1,077,230 | 1,774,699 | 1,943,202 | 1,388,271 | 1,207,343 | 678,013 |
R&D Expenses | -29.6% | 748,339 | 1,062,672 | 1,417,159 | 1,089,342 | 1,869,920 | 1,223,776 | 1,118,141 | - |
EBITDA Margin | 26.6% | -22.01 | -29.99 | -53.07 | -68.94 | -98.33 | -171 | -668 | -3,453 |
Interest Expenses | 87.5% | 59,696 | 31,838 | - | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | - | - | - | -2,552,581 |
EBT Margin | 26.6% | -22.07 | -30.07 | -53.20 | -69.10 | -98.57 | -171 | -670 | -3,464 |
Net Income | 39.1% | -1,653,542 | -2,717,369 | -2,495,580 | -2,797,971 | -3,826,952 | -2,611,835 | -2,322,742 | -29,111,739 |
Net Income Margin | 34.6% | -41.96 | -64.17 | -126 | -162 | -213 | -275 | -930 | -29,659 |
Free Cashflow | 17.4% | -1,497,378 | -1,813,707 | -2,849,246 | -2,190,545 | -2,609,420 | -2,033,922 | -1,999,256 | -3,497,308 |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q2 |
Assets | -20.1% | 6.00 | 8.00 | 9.00 | 12.00 | 14.00 | 17.00 | 20.00 | 16.00 | 17.00 | 19.00 | 21.00 | 22.00 | 4.00 | 3.00 |
Current Assets | -21.2% | 5.00 | 7.00 | - | 12.00 | - | - | - | - | - | - | - | - | 4.00 | 3.00 |
Cash Equivalents | -22.5% | 5.00 | 7.00 | 9.00 | 11.00 | 14.00 | 16.00 | 19.00 | 15.00 | 17.00 | 18.00 | 19.00 | 20.00 | 3.00 | 3.00 |
Liabilities | -0.3% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 11.00 | - |
Shareholder's Equity | -23.2% | 5.00 | 6.00 | 8.00 | 11.00 | 13.00 | 16.00 | 19.00 | 15.00 | 17.00 | 19.00 | 20.00 | 21.00 | - | - |
Retained Earnings | -2.7% | -64.10 | -62.40 | -59.68 | -57.20 | -54.71 | -51.91 | -48.08 | -45.47 | -43.15 | -41.27 | -40.20 | -38.64 | -9.53 | -0.18 |
Additional Paid-In Capital | 0.2% | 69.00 | 69.00 | 68.00 | 68.00 | 68.00 | 67.00 | 67.00 | 61.00 | 60.00 | 60.00 | 60.00 | 60.00 | 0.00 | - |
Shares Outstanding | 0% | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 17.4% | -1,497 | -1,813 | -2,726 | -2,849 | -2,190 | -2,609 | -2,033 | -1,999 | -1,461 | -1,198 | -777 | -3,497 | -828 | -410 | -134 | -150 |
Share Based Compensation | 0% | 200 | 200 | 200 | 242 | 224 | 200 | 200 | 227 | 125 | 94.00 | 34.00 | 115 | 47.00 | 21.00 | 16.00 | - |
Cashflow From Financing | - | - | - | - | -68.16 | - | -248 | 6,699 | - | - | - | - | - | - | - | - | 3,176 |
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||||
Research and development | $ 748,339 | $ 1,089,342 | $ 3,081,231 | $ 4,183,038 |
General and administrative | 915,912 | 1,774,699 | 3,887,157 | 5,106,172 |
Total operating expenses | 1,664,251 | 2,864,041 | 6,968,388 | 9,289,210 |
Loss from operations | (1,664,251) | (2,864,041) | (6,968,388) | (9,289,210) |
Other (income) expenses: | ||||
Interest expense | 59,696 | 91,534 | ||
Interest income | (68,084) | (79,152) | (198,804) | (92,401) |
Other | (2,321) | 13,082 | (9,384) | 39,949 |
Other income, net | (10,709) | (66,070) | (116,654) | (52,452) |
Net loss | $ (1,653,542) | $ (2,797,971) | $ (6,851,734) | $ (9,236,758) |
Weighted average common shares outstanding, basic | 25,933,217 | 25,633,217 | 25,784,853 | 24,888,916 |
Weighted average common shares outstanding, diluted | 25,933,217 | 25,633,217 | 25,784,853 | 24,888,916 |
Net loss per share, basic | $ (0.06) | $ (0.11) | $ (0.27) | $ (0.37) |
Net loss per share, diluted | $ (0.06) | $ (0.11) | $ (0.27) | $ (0.37) |
Condensed Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Jun. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,147,139 | $ 11,247,403 |
Prepaid expenses | 223,676 | 422,748 |
Total current assets | 5,370,815 | 11,670,151 |
Other assets: | ||
Loan commitment fees | 624,820 | |
Total assets | 5,995,635 | 11,670,151 |
Current liabilities: | ||
Accounts payable | 384,920 | 534,545 |
Accrued expenses | 625,401 | 534,256 |
Total liabilities | 1,010,321 | 1,068,801 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 2,000,000 shares authorized, no shares issued or outstanding at March 31, 2024 and June 30, 2023 | ||
Common stock, $0.001 par value; 50,000,000 and 40,000,000 shares authorized at March 31, 2024 and June 30, 2023, respectively; 25,933,217 and 25,633,217 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively | 25,934 | 25,634 |
Additional paid-in capital | 69,013,155 | 67,777,757 |
Accumulated deficit | (64,053,775) | (57,202,041) |
Total stockholders’ equity | 4,985,314 | 10,601,350 |
Total liabilities and stockholders’ equity | $ 5,995,635 | $ 11,670,151 |